Keyphrases
YKL-40
100%
Glioblastoma
99%
Bevacizumab
75%
Recurrent Glioblastoma
52%
Overall Survival
46%
Newly Diagnosed Glioblastoma
44%
Glioma
38%
Hazard Ratio
33%
Adrenocorticotropic Hormone
33%
Genetic Variation
33%
Interleukin-6
33%
ICOS Ligand
33%
Hazard Rate
33%
Interleukin-8
33%
Bevacizumab Therapy
33%
Copeptin
33%
Glucagon
33%
Immune Regulation
33%
Pituitary
33%
Growth Hormone
33%
Renin-angiotensin System Inhibitors
33%
Systemic Immune Response
33%
Prognostic Value
33%
Prognostic Biomarker
33%
Radial Glial Cells
33%
Brain Development
33%
Vascular Endothelial Growth Factor
33%
Brainstem
22%
Progression-free Survival
19%
Confidence Interval
18%
Model Choice
16%
Immunoreactivity
15%
Brain Tumor Microenvironment
13%
WHO Grade II
13%
Tumor Microenvironment
13%
Glucagon Receptor
12%
Angiogenic
11%
High-plex
11%
Spatiotemporal Difference
11%
Indusium Griseum
11%
GeoMx
11%
Cell-based Medicine
11%
Glioblastoma Cell Lines
11%
Regional Heterogeneity
11%
Neuron Cells
11%
Cell Expansion
11%
Faculty of Health Sciences
11%
Neurological Diseases
11%
Olfactory Bulb
11%
Developmental Neuroscience
11%
Neuroscience
Bevacizumab
66%
Brain Tumor
38%
Genetic Variation
33%
Interleukin 6
33%
Glucagon
33%
Radial Glial Cell
33%
Bovine Somatotropin
33%
Growth Hormone Treatment
33%
Inducible T Cell Costimulator Ligand
33%
Copeptin
33%
Vasculotropin A
33%
Interleukin 8
33%
Adrenocorticotropic Hormone
33%
Brainstem
22%
Angiogenesis Inhibitor
16%
Vasculotropin Antibody
16%
Vascular Endothelial Growth Factor
16%
Immunotherapy
16%
Placebo
13%
Glucagon Receptor
12%
Developmental Neuroscience
11%
Cell Line
11%
Apolipoprotein
11%
Glial Cells
11%
Indusium griseum
11%
Brain Development
11%
Cerebellum
11%
Cell Migration
11%
Cell Expansion
11%
Cerebellar Cortex
11%
Entorhinal Cortex
11%
Central Nervous System
11%
Nervous System Disorder
11%
Olfactory Bulb
11%
Argipressin
8%
Radiation Therapy
6%
Glycoprotein
6%
Temozolomide
6%
Astrocytoma
5%
Oligodendrocyte
5%
Medicine and Dentistry
Glioblastoma
92%
Ganglioglioma
38%
Biological Marker
37%
Overall Survival
33%
Interleukin 6
33%
Vasculotropin A
33%
Glucagon
33%
Corticotropin
33%
Growth Hormone
33%
Copeptin
33%
Inducible T Cell Costimulator Ligand
33%
Immunomodulation
33%
Genetic Variation
33%
Hypophysis Function
33%
Interleukin 8
33%
Tumor Microenvironment
24%
Hazard Ratio
23%
Brain Tumor
18%
Bevacizumab
13%
Secretion (Process)
13%
Glucagon Receptor
12%
Neoplasm
11%
Glioblastoma Cell Line
9%
Immune Disorder
8%
Argipressin
8%
Univariate Analysis
7%
Targeted Therapy
6%
Clinical Trial
6%
Vasculotropin Antibody
6%
Clinical Study
6%
Immunotherapy
6%
Angiogenesis Inhibitor
6%
Vasculotropin
6%
